Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Targeted therapy demonstrated high response rates for thyroid tumors with RET mutations or fusions.
The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.
New site-agnostic therapies highlight the importance of genetic testing.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
A new therapy, BLU-667, shows broad antitumor activity against cancers with a variety of RET alterations.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.